Please login to the form below

Moderna

This page shows the latest Moderna news and features for those working in and with pharma, biotech and healthcare.

AZ makes gene therapy move with 4DMT alliance

It also has a long-running collaboration with Moderna seeking messenger RNA drugs for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology, and is

Latest news

Morning brief: New biotech launched, Merck and Moderna expand collaboration and more

A rapid round up of pharma, biotech and healthcare news. Merck and Moderna expand cancer vaccines work. ... The two companies have now added to their collaboration shared antigen mRNA cancer vaccines including mRNA-5671, Moderna’s mRNA KRAS cancer
BMS to explore new options for its immuno-oncology drug Opdivo

Like BMS, Merck &Co has also moved to extend the reach of its immuno-oncology drug, teaming up with Moderna Therapeutics to develop personalised cancer vaccines that would work alongside Keytruda.
Merck & Co signs cancer vaccines research deal for Keytruda

The deal with Moderna Therapeutics will see it use the Cambridge, Massachusetts-based company's novel messenger RNA (mRNA)-based vaccine technology. ... Moderna's mRNA vaccine technology uses the unique mutations present in a patient's tumour to provoke
mRNA - message received

Shire. Eukarys. monogenic liver diseases; Wilson disease. Moderna Therapeutics. cancer; cardiovascular disease; infectious disease; metabolism. ... Valera LLC (Moderna Therapeutics). Infectious diseases. Merck &Co; Pasteur Institute. No clinical
AZ and Redx collaborate on genetics of cancer

Research will take place at Alderley Park site

More from news
Approximately 3 fully matching, plus 11 partially matching documents found.

Latest Intelligence

Deal Watch September 2016

Deal Watch September 2016. Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... up. Turning to the battle against the Zika virus, BARDA announced three more grants for vaccine development to Takeda (up
Deal Watch June 2016

Apart from the $200m upfront cash payment to Moderna, there were no other financials disclosed. ... licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery).
Deal Watch October 2015

Whilst considering nucleic acid-based approaches, it was interesting to see that mRNA company Moderna Therapeutics, which has a number of deals under its belt with AstraZeneca, Alexion and Merck &Co, ... This is Moderna's fourth venture in what it calls
Deal Watch table for January 2014

144. Moderna Therapeutics/ Alexion Pharmaceuticals. Exclusive discovery and development. Messenger RNA (mRNA) therapeutics in rare diseases for 10 product options.
Deal Watch table for October 2013

Moderna Therapeutics / DARPA. R&D grant. mRNA therapeutics for biodefence targets (discovery).

More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest appointments

Tony de Fougerolles joins Evox Therapeutics as CEO

Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.
Medicxi appoints former GSK chair Moncef Slaoui

Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.
MIT chief financial officer joins Moderna Therapeutics

MIT chief financial officer joins Moderna Therapeutics. Israel Ruiz to serve as audit committee chair on its board of directors. ... US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee
PureTech Health appoints chief scientific officer

Bringing over 30 years of clinical development experience to the role, he joins from Moderna Therapeutics where he most recently served as president and chief scientific officer.
Dr Michael Watson appointed as president of Valera

Dr Michael Watson appointed as president of Valera. Former Sanofi Pasteur policy head joins Moderna Therapeutics firm. ... Valera, one of Moderna Therapeutics' venture companies, has appointed Dr Michael Watson as its new president.